Scartozzi, Mario
 Distribuzione geografica
Continente #
NA - Nord America 1.425
AS - Asia 789
EU - Europa 447
SA - Sud America 250
AF - Africa 85
Totale 2.996
Nazione #
US - Stati Uniti d'America 1.379
SG - Singapore 278
BR - Brasile 205
CN - Cina 182
HK - Hong Kong 149
VN - Vietnam 90
SE - Svezia 89
IT - Italia 85
DE - Germania 61
GB - Regno Unito 53
CI - Costa d'Avorio 40
CA - Canada 30
RU - Federazione Russa 29
AT - Austria 28
AR - Argentina 23
TR - Turchia 23
BG - Bulgaria 21
FR - Francia 20
FI - Finlandia 15
SN - Senegal 15
BD - Bangladesh 12
NL - Olanda 12
IQ - Iraq 10
ES - Italia 9
JP - Giappone 9
ZA - Sudafrica 8
MX - Messico 7
EC - Ecuador 6
EG - Egitto 6
ID - Indonesia 6
IN - India 6
NG - Nigeria 6
VE - Venezuela 6
PK - Pakistan 5
CZ - Repubblica Ceca 4
UA - Ucraina 4
AL - Albania 3
RO - Romania 3
SA - Arabia Saudita 3
UY - Uruguay 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
BE - Belgio 2
BS - Bahamas 2
CL - Cile 2
CR - Costa Rica 2
KE - Kenya 2
LT - Lituania 2
MY - Malesia 2
NP - Nepal 2
PA - Panama 2
PL - Polonia 2
PY - Paraguay 2
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CG - Congo 1
CO - Colombia 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GD - Grenada 1
GH - Ghana 1
IE - Irlanda 1
IS - Islanda 1
JO - Giordania 1
KH - Cambogia 1
LB - Libano 1
LY - Libia 1
MA - Marocco 1
MK - Macedonia 1
MU - Mauritius 1
PE - Perù 1
SI - Slovenia 1
SV - El Salvador 1
TJ - Tagikistan 1
TM - Turkmenistan 1
TN - Tunisia 1
Totale 2.996
Città #
Ashburn 202
Singapore 158
Santa Clara 147
Hong Kong 146
Chandler 102
Fairfield 81
Shanghai 77
Woodbridge 64
Dallas 57
New York 41
Abidjan 40
Council Bluffs 39
Houston 36
Boardman 34
Wilmington 34
Cambridge 31
Seattle 31
Beijing 26
Munich 24
Princeton 24
Colorado Springs 23
Vienna 23
Florence 22
Ho Chi Minh City 21
Lawrence 21
Sofia 21
Los Angeles 20
Istanbul 18
Medford 16
Dakar 15
Hanoi 15
London 15
Bremen 14
Ann Arbor 13
Ottawa 13
Buffalo 12
Milan 12
São Paulo 12
Frankfurt am Main 10
Kent 9
Nuremberg 9
Redondo Beach 9
San Diego 9
Haiphong 8
Turku 8
Dearborn 7
Des Moines 7
Poplar 7
Tokyo 7
Chicago 6
Dong Ket 6
Fuzhou 6
Mexico City 6
Montreal 6
Serra 6
Guangzhou 5
Helsinki 5
Johannesburg 5
Lagos 5
Lauterbourg 5
Nanjing 5
Orem 5
Phoenix 5
Redwood City 5
Baghdad 4
Bexley 4
Boston 4
Joinville 4
Lancaster 4
Murcia 4
Ogden 4
Porto Alegre 4
Quanzhou 4
Seacroft 4
Stockholm 4
Amsterdam 3
Bitonto 3
Brasília 3
Brooklyn 3
Caracas 3
Chennai 3
Denver 3
Elk Grove Village 3
Hebei 3
Hải Dương 3
Izmir 3
Karachi 3
Manaus 3
Manchester 3
Montevideo 3
Nanchang 3
Olinda 3
Quito 3
Rio de Janeiro 3
Sorocaba 3
Tirana 3
Turin 3
Abbiategrasso 2
Ankara 2
Augusta 2
Totale 1.987
Nome #
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 168
Natural history of malignant bone disease in hepatocellular carcinoma: Final results of a multicenter bone metastasis survey 166
Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol 141
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 122
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 120
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158) 119
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 117
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: A fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis 117
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 115
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 109
Cholangiocarcinoma: new perspectives for new horizons 106
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 103
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 103
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 100
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer 100
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 99
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 98
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 98
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 98
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 91
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 91
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 90
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 89
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 87
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 85
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 78
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 54
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 52
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis 42
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis 42
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 20
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 7
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 6
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 6
Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance 6
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 6
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 6
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 5
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 5
Totale 3.067
Categoria #
all - tutte 10.856
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.856


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202145 0 0 0 0 0 9 2 6 4 4 3 17
2021/2022186 3 8 4 1 11 50 3 11 5 21 21 48
2022/2023396 38 60 32 24 40 45 6 24 88 2 31 6
2023/2024173 14 15 23 4 20 24 15 14 7 1 14 22
2024/20251.033 2 73 33 51 108 172 53 48 95 116 102 180
2025/2026890 108 186 135 191 148 122 0 0 0 0 0 0
Totale 3.067